Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance

Labcorp’s Q3 2026 revenue rose 6.9% to $3.81 billion and adjusted EPS increased 14.5% to $4.78; diluted EPS was $3.22, up 3.3%. The company raised 2026 enterprise revenue-growth guidance to 5.9%–6.7% and adjusted EPS guidance to $18.30–$18.70, increases of 50 basis points and 18 cents at the midpoints, respectively. Labcorp announced or closed four acquisitions, each expected to be accretive to adjusted EPS in year one, and received FDA approval for a companion diagnostic for advanced melanoma.

Analysis

The quality of the beat is mixed beneath the adjusted headline: adjusted operating margin improved, but GAAP operating income barely advanced and the gap widened as quarterly adjustments rose materially. That makes the durability of cost savings—not another adjusted EPS beat—the key test. The 2026 guidance increase is constructive, though unchanged free-cash-flow guidance and working-capital support for quarterly cash generation limit the read-through to cash earnings.

Growth is increasingly split: Central Labs strength and improving Biopharma margins contrast with near-flat Early Development growth. The order book supports near-term Biopharma visibility, but it does not remove exposure to delayed or canceled drug-development programs. The acquisitions could broaden specialty and women’s-health offerings, while also raising integration demands: cash was $261.8 million against $5.85 billion of debt, and the announced transactions’ prices, funding, and standalone economics are not supplied. Accretion claims are management expectations, not verified outcomes.

For competitors, Labcorp’s expanded specialty and prenatal testing footprint raises competitive pressure on Quest Diagnostics and may divert business from Myriad Genetics’ retained portfolio; the actual impact depends on transaction terms and customer retention. Waters Corporation’s role in commercializing HPV testing appears strategically useful but is not yet evidence of material earnings contribution. Contrarian point: the headline EPS growth overstates the clean operating acceleration; watch GAAP margins, receivables, and acquisition-adjusted cash conversion. Without valuation and current-price context, avoid chasing the print.

Key Decisions for Investors

• LH: Prefer a staged entry after the initial earnings reaction rather than chasing strength. Reassess after the 9 a.m. ET call for evidence that organic growth and segment margin gains support the raised outlook. Thesis weakens if guidance is walked back or GAAP operating margin continues to contract.
• Track cash conversion over the next 1–3 quarters: quarterly free cash flow benefited from working capital, while receivables rose and full-year FCF guidance did not change. A sustained increase in receivables relative to revenue, or a cut to FCF guidance, would argue against paying for adjusted EPS momentum.
• Treat the acquisitions as a watch item, not an immediate earnings upgrade: verify purchase prices, financing, regulatory close dates, and retention/integration costs. The stated accretion and cost-of-capital timelines are company expectations; funding needs could constrain buybacks or increase leverage.
• MYGN: Do not trade the announced prenatal-business sale on headline alone. Verify proceeds, stranded costs, and post-sale growth profile before taking a view; a weak sale price or meaningful lost contribution could outweigh portfolio simplification.